Ignite Creation Date:
2024-07-17 @ 10:52 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06490757
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-08
First Post:
2024-06-24
Brief Title:
A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular Adenomas
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Assistance Publique - Hôpitaux de Paris
Study Overview
Official Title:
A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular Adenomas
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
JAKIH
Brief Summary:
Hepatocellular adenomas HCA are tumors rare benign hepatic infections that develop on a liver normal and in young women taking a estrogen-based contraception The main molecular subgroup of AHCs is the AHC subgroup inflammatory which are associated with a risk of bleeding from the tumor and malignant transformation Therefore most of women with large inflammatory AHC 5 cm require liver resection which can be associated with morbidity and aesthetic problems and rarely to mortality On the basis of the knowledge of the molecular classification of AHCs humans and preclinical data testing the JAK12 inhibitors we hypothesize that a short duration of treatment with the inhibitor of JAK12 baricitinib may be effective in patients with large inflammatory AHC size
Detailed Description:
Hepatocellular adenomas HCA are tumors rare benign hepatic infections that develop on a liver normal and in young women taking a estrogen-based contraception The main molecular subgroup of AHCs is the AHC subgroup inflammatory characterized by activation of the pathway JAKSTAT due to mutations in IL6ST STAT3 FRK JAK1 or GNAS with inflammatory infiltrates at histology Hepatocellular adenomas are associated with a risk of bleeding from the tumor and malignant transformation Therefore most of women with large inflammatory AHC 5 cm require liver resection which can be associated with morbidity and aesthetic problems and rarely to mortality On the basis of the knowledge of the molecular classification of AHCs humans and preclinical data testing the JAK12 inhibitors we hypothesize that a short duration of treatment with the inhibitor of JAK12 baricitinib may be effective in patients with large inflammatory AHC size
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None